Once-Monthly MariTide Promising in Phase 2 Despite GI Issues
CHICAGO — Patients with obesity with or without diabetes lost as much as 20% of body weight and showed reductions in A1c levels, after 1 year of treatment with the novel agent maridebart cafraglutide (MariTide), according to the results of a Phase 2 study. However, virtually all patients experienced a gastrointestinal (GI) adverse event, leading […]
Once-Monthly MariTide Promising in Phase 2 Despite GI Issues Read More »
